Biomarkers and mechanisms of drug-induced vascular injury in non-rodents

Toxicologic Pathology

Volumn 34, Issue 1, 2006, Pages 19-26

  Louden, Calvert ^a,b   Brott, David ^b   Katein, Anne ^b   Kelly, Thomas ^b   Gould, Sarah ^a   Jones, Huw ^a   Betton, Graham ^a   Valetin, Jean Pierre ^a   Richardson, Rudy ^b  

^a ASTRAZENECA   (United Kingdom)

^b University of Michigan ^*  (United Kingdom)

Author keywords

Biomarker; Caveolin 1; Drug induced vascular injury; Nitric oxide; Von Willebrand Factor; Von Willebrand Factor propeptide

Indexed keywords

3 (2 CARBOXYMETHOXY 4 METHOXYPHENYL) 1 (3,4 METHYLENEDIOXYPHENYL) 5 PROPOXY 2 INDANCARBOXYLIC ACID; 3 [4 [3 (3 METHOXY 5 METHYL 2 PYRAZINYLSULFAMOYL) 2 PYRIDYL]PHENYL] 2,2 DIMETHYLPROPIONIC ACID; 6 [4 (1,4 DIHYDRO 4 OXO 1 PYRIDYL)PHENYL] 4,5 DIHYDRO 5 METHYL 3(2H) PYRIDAZINONE; ADENOSINE; ADENOSINE DERIVATIVE; ADENOSINE RECEPTOR STIMULATING AGENT; ANTIHYPERTENSIVE AGENT; ARGIPRESSIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CAVEOLIN; ENDOTHELIN RECEPTOR ANTAGONIST; FENOLDOPAM; HYDRALAZINE; IMAZODAN; INDOLIDAN; MINOXIDIL; N (2,2 DIPHENYLETHYL)ADENOSINE; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE; POTASSIUM CHANNEL STIMULATING AGENT; SIGUAZODAN; SMOOTH MUSCLE ACTIN; UNCLASSIFIED DRUG; VASCULOTROPIN; VASOACTIVE AGENT; VASOCONSTRICTOR AGENT; VASODILATOR AGENT; VON WILLEBRAND FACTOR;

BLOOD FLOW; BLOOD VESSEL INJURY; CELL DAMAGE; CORONARY ARTERY BLOOD FLOW; DISEASE MARKER; DRUG ACTIVITY; DRUG INDUCED DISEASE; ENDOTHELIUM CELL; HEART RATE; HUMAN; INFLAMMATION; MEAN ARTERIAL PRESSURE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; SHEAR STRESS; SHORT SURVEY; VASODILATATION;

ANIMALS; BIOLOGICAL MARKERS; DOGS; DRUG EVALUATION, PRECLINICAL; DRUGS, INVESTIGATIONAL; ENDOTHELIUM, VASCULAR; MUSCLE, SMOOTH, VASCULAR; NITRIC OXIDE; VASCULAR DISEASES; VON WILLEBRAND FACTOR;

RODENTIA;

EID: 33644659963     PISSN: 01926233     EISSN: 15331601     Source Type: Journal    
DOI: 10.1080/01926230500512076     Document Type: Short Survey

References (75)

1. Albassam, M. A., Metz, A. L., Potoczak, R. E., Gallagher, K. P., Haleen, S., Hallak, H., and McGuire, E. J. (2001). Studies on coronary arteriopathy in dogs following administration of CI-1020, an endothelin A receptor antagonis. Toxicol Pathol 29, 277-84.
2. Albassam, M. A., Metz, A. L., Gragtmans, N. J., King, L. M., Macallum, G. E., Hallak, H., and McGuire, E. J. (1999). Coronary arteriopathy in monkeys following administration of CI-1020, an endothelin A receptor antagonist. Toxicol Pathol 27, 156-64.
3. Albassam, M. A., Smith, G. S., and Macallum, G. E. (1998). Arteriopathy induced by an adenosine agonist-antihypertensive in monkeys. Toxicol Path 26, 375-80.
4. Anderson, R. G. (1998). The caveolae membrane system. Ann Rev Biochem 67, 199-225.
5. Bacchus, A. N., Ely, S. W., Knabb, R. M., Rubio, R., and Berne, R. M. (1982). Adenosine and coronary blood flow in conscious dogs during normal physiological stimuli. Am J Physiol 243, H628-33.
6. Bishop, S. P., Powell, P. C., Hasebe, N., Shen, Y. I., Patrick, T. A., Hittinger, L., and Vatner S. F. (1996). Coronary vascular morphology in pressure-overload left ventricular hypertrophy. J Mol Cell Cardiol 28, 141-54.
7. Boger, R. H. (2003). The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor. Cardiovasc Res 59, 824-33.
8. Boger, R. H., and Ron, E. S. (2005). L-arginine improves vascular function by overcoming the deleterious effects of ADMA, a novel cardiovascular risk factor. Altern Med Rev 10, 14-23.
9. Borchiellini, A., Fijnvandraat, K., ten Cat, J. W., Pajkrt, D., van Deventer, S. J., Pasterkamp, G., Meijer-Huizinga, F., Zwat-Huinink, L., Voorberg, J., and van Mourik, J. A. (1996). Quantitative analysis of von Willebrand factor propeptide release in vivo: effect of experimental endotoxemia and administration of 1-deamino-8-D-arginine vasopressin in humans. Blood 88, 2951-8.
10. Bouloumie, A., Schini-kerth, V. B., and Busse, R. (1999). Vascular endothelial growth factor up-regulates nitric oxide synthase expression in endothelial cells. Cardiovasc Res 41, 773-80.
11. Brott, D. A., Jones, H. B., Gould, S., Valentin, J. P., Evans, G., Richardson, R. J., and Louden, C. (2005a). Current status and future directions for diagnostic markers of drug-induced vascular injury. Cancer Biomarkers 1, 15-28.
12. Brott, D., Gould, S., Jones, H., Schofield, J., Prior, H., Valentin, J. P., Bjurstrom, S., Kenne, K., Schuppe-Koistinen, I., Katein, A., Foster-Brown, L., Betton, G., Richardson, R., Evans, G., and Louden, C. (2005b). Biomarkers of drug-induced vascular injury. Toxicol Appl Pharmacol 207, S441-5.
13. Bucci, M., Gratton, J. P., Rudic, R. D., Acevedo, L., Roviezzo, F., Cirino, G., and Sessa, W. C. (2000). In vivo delivery of the caveolin-1 scaffolding domain inhibits nitric oxide synthesis and reduces inflammation. Nat Med 6, 1362-7.
14. Bussolati, B., Dunk, C., Groham, M., Kontos, C. D., Mason, J., and Ahmed, A. (2001). Vascular endothelial growth factor receptor-1 modulates vascular endothelial factor-mediated angiogenesis via nitric oxide. Am J Pathol 159, 993-1008.
15. Chelly, J. E., Doursout, M. F., Begaud, B., Tsao, C. C., and Hartley, C. J. (1986). Effects of hydralazine on regional blood flow in conscious dogs. J Pharmacol Exp Ther 238, 665-9.
16. Clemo, F. A. S., Evering, W. E., Snyder, P. W., and Albassam, M. A. (2003). Differentiating spontaneous from drug-induced vascular injury in the dog. Toxicol Pathol 31, 25-31.
17. Cuevas, P., Carceller, F., Ortega, S., Zazo, M., and Gimenez-Gallego, G. (1991). Hypotensive activity of fibroblast growth factor. Science 254, 1208-10.
18. Dogterom, P., Zbinden, G., and Rezik G. K. (1992). Cardiotoxicity of vasodilators and positive inotropic/vasodilating drugs in dogs: an overview. Crit Rev Toxciol 22, 203-41.
19. Drab, M., Verkade, P., Elger, M., Kasper, M., Lohn, M., Lauterbach, B., Menne, J., Lindschau, C., Mende, F., Luft, F., Schedl, A., Haller, H., and Kurzchalia, T. V. (2001). Loss of caveolae, vascular dysfunction, and pulmonary defects in Caveolin-1 gene-disrupted mice. Science 293, 2449-52.
20. Fattman, C. L., Schaefer, L. M., and Oury, T. D. (2003). Extracellular superoxide dismutase in biology and medicine. Free Radic Biol Med 35, 236-56.
21. Feron, O., and Kelly, R. A. (2001). The caveolar paradox: suppressing, inducing and terminating eNOS signaling. Circ Res 88, 129-31.
22. Garcia-Cardena, G., Marasek, P., Masters, B. S., Skidd, P. M., Couet, J., Li, S., Lisanti, M. P., and Sessa, W. C. (1997). Dissecting the interaction between nitric oxide synthase (NOS) and caveolin. J Biol Chem 272, 25437-40.
23. Goligorsky, M. S., Li, H., Brodsky, S., and Chen, J. (2002). Relationships between caveolae and eNOS: everything in proximity and the proximity of everything. Am J Physiol Renal Physiol 283, F1-10.
24. Gorenflo, M., Zheng, C., Werle, E., Fiehn, W., and Ulmer, H. E. (2001). Plasma levels of asymmetrical dimethyl-L arginine in patients with congenital heart disease and pulmonary hypertension. J Cardiovasc Pharmacol 37, 489-92.
25. Haas, M., Meehan, S. M., Josephson, M. A., Wit, E. J., Woodle, E. S., and Thistlethwaite, J. R. (1999). Smooth muscle-specific actin levels in urine of renal transplant recipients: correlation with cyclosporine or tacrolimus nephrotoxicity. Am J Kidney Dis 34, 69-84.
26. Hariawala, M. D., Horowitz, J. R., Esakof, D., Sheriff, D. D., Walter, D. H., Keyt, B., Isner, J. M., and Symes, J. F. (1996). VEGF improves myocardial blood flow but produces EDRF-mediated hypotension in porcine hearts. J Surg Res 63, 77-82.
27. Hennequin, L. F., Thomas, A. P., Johnstone, C., Stokes, E. S., Ple, P. A., Lohmann, J. J., Ogilvie, D. J., Dukes, M., Wedge, S. R., Curwen, J. O., Kendrew, J., and Lambert-van der Brempt, C. (1999). Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine inhibitors. J Med Chem 42, 5369-89.
28. Herman, E. H., Ferrans, V. J., Young, R. S., and Balazs, T. (1989). A comparative study of minoxidil-induced myocardial lesions in beagle dogs and miniature swine. Toxicol Pathol 17, 182-92.
29. Horowitz, J., and Hariawala, M. (1995). In vivo administration of vascular endothelial growth factor is associated with EDRF-dependent decrease in systemic hypotension in porcine and rabbit. Circulation 92, S16-20.
30. Humphrey, S. J., and Zins, G. R. (1984). Whole body and regional hemodynamic effects of minoxidil in conscious dogs. J Cardiovasc Pharmacol 6, 979-88.
31. Isaacs, K. R., Joseph, E. C., and Betton, G. R. (1989). Coronary vascular lesions in dogs treated with phosphodiesterase III inhibitors. Toxicol Pathol 17, 153-63.
32. Ishizaka, N., Griendling, K. K., Lassegue, B., and Alexander, R. W. (1998). Angiotensin II type 1 receptor: relationship with caveolae and caveolin after initial agonist stimulation. Hypertension 32, 459-66.
33. Jones, H. B., Macpherson, A., Betton, G. R., Davis, A. S., Siddall, R., and Greaves, P. (2003). Endothelin antagonist-induced coronary and systemic arteritis in the beagle dog. Toxicol Pathol 31, 263-72.
34. 1 agonists. Toxicol Lett 112-113, 537-46.
35. Joseph, E. C., Mesfin, G., and Kerns, W. D. (1997). Pathogenesis of arterial lesions caused by vasoactive compounds in laboratory animals. In Cardiovascular Toxicology (S. P. Bishop and W. D. Kerns, eds). Pergamon, New York, pp 279-307.
36. Joseph, E. C., Jones, H. B., and Kerns, W. D. (1996). Characterization of coronary arterial lesions in the dog following administration of SK&F 95654, a phosphodiesterase III inhibitor. Toxicol Pathol 24, 429-35.
37. Kielstein, J. T., Boger, R. H., Bode-Boger, S. M., Frolich, J. C., Haller, H., Ritz, E., and Fliser, D. (2002). Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease. J Am Soc Nephrol 13, 170-6.
38. Ku, D. D., Zaleski, J. K., Liu, S., and Brock, T. A. (1993). Vascular endothelial growth factor induces EDRF-dependent relaxation in coronary arteries. Am J Physiol 265, H585-92.
39. Labrecque, L., Royal, I., Surprenant, D. S., Patterson, C., Gingras, D., and Beliveau, R. (2003). Regulation of vascular endothelial growth factor receptor-2 activity by caveolin-1 and plasma membrane cholesterol. Mol Biol Cell 14, 334-17.
40. Liu, P., Rudick, M., and Anderson, R. G. (2002). Multiple functions of caveolin-1. J Bio Chem 277, 41295-8.
41. Louden, C., Nambi, T.P., Branch, C., Gossett, K., Pullen, M., Eustis, S., and Solleveld, H. A. (1998). Coronary arterial lesions in dogs treated with an endothelin receptor antagonist. J Cardiovasc Pharmacol 31, S384-5.
42. Louden, C. S., Nambi, P., Pullen, M. A., Thomas, R. A., Tiernery, L. A., Solleveld, H. A., and Schwartz, L. W. (2000). Endothelin receptor subtype distribution predisposes coronary arteries to damage. Am J Pathol 157, 123-34.
43. Macallum, G. E., Walker, R. M., Barsoum, N. J., and Smith, G. S. (1991). Preclinical toxicity studies of an adenosine agonist, N-(2,2-diphenylethyl) adenosine. Toxicology 68, 21-35.
44. McDuffie, E., Yu, X., Song, Y, and Albassam, M. (2004). Potential markers of acute coronary artery injury in dogs following administration of CI-1034, an endothelin a receptor antagonist. Toxicologist 78(1S), 1820.
45. McFarland, D. C., Scicchitano, M. S., Thomas, R. A., Narayanan, P. K., Schwartz, L. W., and Thomas, H. C. (2004). 6-color flow-sorting of rat circulating endothelial cells and taqman real-time PCR analysis. Cytometry 59A, 65.
46. McIntosh, D. P., Tan, S. Y., Oh, P., and Schnitze, J. E. (2002). Targeting endothelium and its dynamic caveolae for tissue-specific transcytosis in vivo: a pathway to overcome cell barriers to drug and gene delivery. Proc Natl Acad Sci USA 99, 1996-2001.
47. Mesfin, G. M., Higgins, M. J., Robinson, F. G., and Zhong, W. Z. (1996). Relationship between serum concentrations, hemodynamic effects, and cardiovascular lesions in dogs treated with minoxidil. Toxicol Appl Pharmacol 140(2), 337-44.
48. Mesfin, G. M., Piper, R. C., DuCharme, D. W., Carlson, R. G., Humphrey, S. J., and Zins, G. R. (1989). Pathogenesis of cardiovascular alterations in dogs treated with minoxidil. Toxicol Pathol 17, 164-81.
49. Mesfin, G. M., Shawaryn, G. G., and Higgins, M. J. (1987). Cardiovascular alterations in dogs treated with hydralazine. Toxicol Pathol 15, 409-16.
50. Metz, A. L., Dominick, M. A., Suchanek, G., and Gough, A. W. (1991). Acute cardiovascular toxicity induced by an adenosine agonist-antihypertensive in beagles. Toxicol Pathol 19, 98-107.
51. Morgan, D. G., Bugelski, P. J., Berkowitz, B. A., Valocik, E., and Arena, E. (1983). Medial necrosis and hemorrhage in arteries of rats infused with a dopaminergic agents. Lab Invest 48, 46A.
52. Mosca, L. (2002). C-reactive protein - to screen or not to screen? N Engl J Med 347, 1615-7.
53. Newsholme, S. J., Thudium, D. T., Gossett, K. A., Watson, E. S., and Schwartz, L. W. (2000). Evaluation of plasma von Willebrand factor as a biomarker for acute arterial damage in rats. Toxicol Pathol 28, 688-93.
54. Park, H., Go, Y. M., Darji, R., Choi, J. W., Lisanti, M. P., Maland, M. C., Jo, H. (2000). Caveolin regulates shear stress-dependent activation of extracellular signal-regulated kinase. Am J Physiol Heart Circ Physiol 278, H1285-93.
55. Pridjian, G., and Puschett, J. B. (2002). Preeclampsia. Part 1: clinical and pathophysiologic considerations. Obstet Gynecol Surv 57, 598-618.
56. Ridker, P. M. (2003). Clinical applications of c-reactive protein for cardiovascular disease detection and prevention. Circulation 107, 363-9.
57. Rizzo, V., McIntosh, D. P., Oh, P., and Schnitzer, J. E. (1998). In situ flow activates endothelial nitric oxide synthase in luminal caveolae of endothelium with rapid caveolin dissociation and calmodulin association. J Biol Chem 273, 34724-9.
58. Roberts, J. M., and Cooper, D. W. (2001). Pathogenesis and genetics of preeclampsia. Lancet 357, 53-6.
59. Roberts, J. M., Taylor, R. N., Musci, T. J., Rodgers, G. M., Hubel, C. A., and McLaughlin, M. K. (1989). Preeclampsia: an endothelial cell disorder. Am J Obstet Gynecol 161, 1200-4.
60. Rothberg, K. G., Heuser, J. E., Donzell, W. C., Ying, Y. S., Glenney, J. R., and Anderson, R. G. (1992). Caveolin, a protein component of Caveolae membrane coats. Cell 68, 673-82.
61. Sabota, J. T. (1989). Review of cardiovascular findings in humans treated with minoxidil. Toxicol Pathol 17, 193-201.
62. Saitoh, M., Osanai, T., Kamada, T., Matsunaga, T., Ishizaka, H., Hanada, H., and Okumura, K. (2003). High plasma level of asymmetric dimethylarginine in patients with acutely exacerbated congestive heart failure: role in reduction of plasma nitric oxide level. Heart Vessels 18, 177-82.
63. Sandusky, G. E., Means, J. R., and Yeager, H. K. (1993). Coronary artery toxicity in beagle dogs given indolidan, a type III phosphodiesterase inhibitor. Fundam Appl Toxicol 21, 228-35.
64. Scicchitano, M., Thomas, R., McFarland, D., Narayanan, P., Thomas, H., Tierney, L., and Schwartz, L. (2003). Transcriptional phenotyping of circulating endothelial cells form sorted rat whole blood. Vet Pathol 40, 626a.
65. Schwartz, C. T., Sprague, E. A., Valente, A. J., Kelley, J. M., and Edwards, E. H. (1989). Cellular mechanisms in the response of the arterial wall to injury and repair. Toxicol Pathol 17, 66-71.
66. Shaul, P. W., and Anderson, R. G. (1998). Role of plasmalemmal caveolae in signal transduction. Am J Physiol 275: L843-51.
67. Stephan-Gueldner, M., and Inomata, A. (2000). Coronary arterial lesions induced by endothelin antagonists. Toxicol Lett 112-113, 531-5.
68. Vallance, P., and Leiper, J. (2004). Cardiovascular biology of the asymmetric dimethylarginine: dimethylarginine dimethylaminohydrolase pathway. Arterioscler Thromb Vasc Biol 24, 1023-30.
69. van Mourik, J. A., Boertjes, R., Huisveld, I. A., Fijnvandraat, K., Pajkrt, D., van Genderen, P. J., and Fijnheer, R. (1999). von Willebrand factor in vascular disorders: a tool to distinguish between acute and chronic endothelial cell perturbation. Blood 94, 179-85.
70. Vischer, U. M., Ingerslev, J., Wollheim, C. B., Mestries, J. C., Tsakiris, D. A., Haefeli, W. E., and Kruithof, E. K. (1997). Acute von willebrand factor secretion from the endothelium in vivo: assessment through plasma propeptide (vWf:AgII) levels. Thromb Haemost 77, 387-93.
71. Yamaguchi, T., Murata, Y., Fujiyoshi, Y., and Doi, T. (2003). Regulated interaction of endothelin B receptor with caveolin-1. Eur J Biochem 270, 1816-27.
72. Yang, R., Thomas, G. R., Bunting, S., Ko, A., Ferrara, N., Keyt, B., Ross, J., and Jin, H. (1996). Effects of vascular endothelial growth factor on hemodynamics and cardiac performance. J Cardiovasc Pharmacol 27, 838-44.
73. Zhang, J., Honchel, R., Weaver, J. L., Knapton, A., Herman, E. H., Goodsaid, F. M., Davis, J. W. II, Rosenblum, I. Y., and Sistare, F. D. (2004). An experimental PDE IV inhibitor-induced vascular injury (VI) associated with increased mast cell degranulation and elevated serum levels of acute-phase proteins in Sprague-Dawley rats. Toxicologist 78(1S), 1821a.
74. Zhao, Y. Y., Liu, Y., Stan, R. V., Fan, L., Gu, Y., Dalton, N., Chu, P. H., Peterson, K., Ross, J. Jr., and Chien, K. R. (2002). Defects in caveolin-1 cause dilated cardiomyopathy and pulmonary hypertension in knockout mice. Proc Natl Acad Sci USA 99, 11375-80.
75. Zoccali, C., Bode-Boger, S. M., Mallamaci, F., Benedetto, F. A., Tripepi, G., Malatino, L. S., Cataliotti, A., Bellanuova, I., Fermo, I., Frolich, J. C., and Boger, R. H. (2001). Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 358, 2113-7.